Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9744159 | 0.82 | P2RX7 (0.35) | ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5808123 | 0.76 | TSHR (0.35) | — | |
| SCHEMBL11414735 | 0.76 | TSHR (0.44) | ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL535464 | 0.76 | GABRA1 (0.44) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5521697 | 0.76 | — | — | |
| SCHEMBL20141749 | 0.76 | — | — | |
| SCHEMBL9036599 | 0.73 | CYP2D6 (0.41) | ALDH1A1CYP1A2 | |
| SCHEMBL8507192 | 0.73 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL8384 | 0.73 | TSHR (0.35) | ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL655520 | 0.73 | CYP1A2 (0.43) | ALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | CHATTOPADHYAYA JYOTI (SE) | 2004-07-22 | — | — | US | claimed |
| EP-1332150-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | Chattopadhyaya, Jyoti (SE) | 2003-08-06 | — | — | EP | claimed |
| WO-2002038578-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | CHATTOPADHYAYA JYOTI (SE) | 2002-05-16 | — | — | WO | claimed |
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| US-5430139-A | Viricides; effective against herpes and cytomegalo viruses | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1995-07-04 | — | — | US | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| US-5300636-A | 2'-alkylidenepyrimidine nucleoside compounds and a process for production of same | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1994-04-05 | — | — | US | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
| US-5189027-A | Hypotensive agent, vasoconstriction | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1993-02-23 | — | — | US | claimed |
| US-5068340-A | Antagonist of platelet activating factor for treatment of asthma, inflammation or shock | SANKYO COMPANY, LIMITED (JP) | 1991-11-26 | — | — | US | claimed |
| US-20240238321-A1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | SYNTHENA AG (CH) | 2024-07-18 | — | — | US | disclosed |
| CN-118355117-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| WO-2024148274-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-4783532-A | Process for preparing griseolic acid derivatives | SANKYO COMPANY LIMITED (JP) | 1988-11-08 | — | — | US | disclosed |
| EP-0260121-A2 | Inosose derivatives, production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-03-16 | — | — | EP | disclosed |
| EP-0240175-A1 | Inosose derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-10-07 | — | — | EP | disclosed |
| EP-0238202-A2 | Glycerol derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1987-09-23 | — | — | EP | disclosed |
| EP-0200522-A2 | Process for preparing griseolic acid derivatives | SANKYO COMPANY LIMITED (JP) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | RNASEH1, RNASEL, NSUN2 | ALDH1A1 4684/4885CYP1A2 3206/4885CYP2C9 2499/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | ALDH1A1 2867/4885CYP1A2 4590/4885CYP2C9 3989/4885 |
| US-20240238321-A1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | MTPN, UTRN, DCTD | ALDH1A1 3954/4885CYP1A2 4607/4885CYP2C9 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.